Nicola Gianotti

Nicola Gianotti

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 131 publications

Well-being in people with HIV after one year of long-acting cabotegravir and rilpivirine.

Well-being in people with HIV after one year of long-acting cabotegravir and rilpivirine.

Journal: AIDS care

Published: September 07, 2026

Hepatitis B Reactivation in People with HIV After Switching to a 2-Drug Anti-HBV Sparing Regimen.

Hepatitis B Reactivation in People with HIV After Switching to a 2-Drug Anti-HBV Sparing Regimen.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: June 22, 2026

Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV.

Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV.

Journal: The Journal of antimicrobial chemotherapy

Published: January 31, 2025

Probability of Starting Two-Drug Regimen (2DR) vs. Three-Drug Regimen (3DR) in ART-Naïve and ART-Experienced Person with HIV (PWH) Across the First Wave of COVID-19 Pandemic.

Probability of Starting Two-Drug Regimen (2DR) vs. Three-Drug Regimen (3DR) in ART-Naïve and ART-Experienced Person with HIV (PWH) Across the First Wave of COVID-19 Pandemic.

Journal: Viruses

Published: September 27, 2024

Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens.

Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens.

Journal: AIDS (London, England)

Published: August 20, 2024

Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting.

Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life setting.

Journal: The Journal of antimicrobial chemotherapy

Published: August 06, 2024

CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine.

CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine.

Journal: AIDS (London, England)

Published: June 07, 2024

One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study.

One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study.

Journal: Open forum infectious diseases

Published: March 29, 2024

Outcome of Darunavir-Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure.

Outcome of Darunavir-Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure.

Journal: Drug design, development and therapy

Published: October 09, 2023

Viral blips and virologic failures following mpox vaccination with MVA-BN among people with HIV.

Viral blips and virologic failures following mpox vaccination with MVA-BN among people with HIV.

Journal: AIDS (London, England)

Published: September 29, 2023

High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy.

High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy.

Journal: AIDS and behavior

Published: September 21, 2023

Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice.

Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice.

Journal: Drug design, development and therapy

Published: September 18, 2023

Showing 1-12 of 131

Last Updated: 09/26/2026